Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

July 18, 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

July 18, 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

July 14, 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

July 12, 2023

As more is understood about the biology of PDAC tumors, targeting common KRAS variants in these tumors following exhaustion of all curative intent surgery, chemotherapy, and radiation ushers in a novel postadjuvant setting for investigators.

July 11, 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

July 11, 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

July 05, 2023

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

July 04, 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

July 04, 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

June 27, 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

June 27, 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

June 23, 2023

Eileen M. O'Reilly, MD, discusses survival outcomes from the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

June 22, 2023

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

June 19, 2023

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

June 14, 2023

The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.

June 13, 2023

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

June 05, 2023

The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.

June 04, 2023

Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.

June 04, 2023

Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.

June 03, 2023

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.